We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Impel Pharmaceuticals Inc | NASDAQ:IMPL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2411 | 0.19 | 0.1901 | 0 | 01:00:00 |
A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.
About Impel Pharmaceuticals Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers, and is developing, treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:Melyssa WeibleElixir Health Public RelationsPhone: (1) 386-366-0616Email: mweible@elixirhealthpr.com
Investor RelationsChristina TartagliaStern Investor RelationsPhone: 212-362-1200Email: christina.tartaglia@sternir.com
1 Year Impel Pharmaceuticals Chart |
1 Month Impel Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions